These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Evaluation of Current Methods to Detect Cellular Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Activity. Fernández B; Chittoor-Vinod VG; Kluss JH; Kelly K; Bryant N; Nguyen APT; Bukhari SA; Smith N; Lara Ordóñez AJ; Fdez E; Chartier-Harlin MC; Montine TJ; Wilson MA; Moore DJ; West AB; Cookson MR; Nichols RJ; Hilfiker S J Parkinsons Dis; 2022; 12(5):1423-1447. PubMed ID: 35599495 [TBL] [Abstract][Full Text] [Related]
11. 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Nichols RJ; Dzamko N; Morrice NA; Campbell DG; Deak M; Ordureau A; Macartney T; Tong Y; Shen J; Prescott AR; Alessi DR Biochem J; 2010 Sep; 430(3):393-404. PubMed ID: 20642453 [TBL] [Abstract][Full Text] [Related]
12. The Roc domain of LRRK2 as a hub for protein-protein interactions: a focus on PAK6 and its impact on RAB phosphorylation. Cogo S; Ho FY; Tosoni E; Tomkins JE; Tessari I; Iannotta L; Montine TJ; Manzoni C; Lewis PA; Bubacco L; Chartier Harlin MC; Taymans JM; Kortholt A; Nichols J; Cendron L; Civiero L; Greggio E Brain Res; 2022 Mar; 1778():147781. PubMed ID: 35016853 [TBL] [Abstract][Full Text] [Related]
13. Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons. Pan PY; Li X; Wang J; Powell J; Wang Q; Zhang Y; Chen Z; Wicinski B; Hof P; Ryan TA; Yue Z J Neurosci; 2017 Nov; 37(47):11366-11376. PubMed ID: 29054882 [TBL] [Abstract][Full Text] [Related]
14. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human. Mir R; Tonelli F; Lis P; Macartney T; Polinski NK; Martinez TN; Chou MY; Howden AJM; König T; Hotzy C; Milenkovic I; Brücke T; Zimprich A; Sammler E; Alessi DR Biochem J; 2018 Jun; 475(11):1861-1883. PubMed ID: 29743203 [TBL] [Abstract][Full Text] [Related]
15. LRRK2 Phosphorylation: Behind the Scenes. De Wit T; Baekelandt V; Lobbestael E Neuroscientist; 2018 Oct; 24(5):486-500. PubMed ID: 29385885 [TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of amyloid precursor protein by mutant LRRK2 promotes AICD activity and neurotoxicity in Parkinson's disease. Chen ZC; Zhang W; Chua LL; Chai C; Li R; Lin L; Cao Z; Angeles DC; Stanton LW; Peng JH; Zhou ZD; Lim KL; Zeng L; Tan EK Sci Signal; 2017 Jul; 10(488):. PubMed ID: 28720718 [TBL] [Abstract][Full Text] [Related]
17. The C-terminal domain of LRRK2 with the G2019S mutation is sufficient to produce neurodegeneration of dopaminergic neurons in vivo. Cresto N; Gaillard MC; Gardier C; Gubinelli F; Diguet E; Bellet D; Legroux L; Mitja J; Auregan G; Guillermier M; Josephine C; Jan C; Dufour N; Joliot A; Hantraye P; Bonvento G; Déglon N; Bemelmans AP; Cambon K; Liot G; Brouillet E Neurobiol Dis; 2020 Feb; 134():104614. PubMed ID: 31605779 [TBL] [Abstract][Full Text] [Related]
18. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease. Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749 [TBL] [Abstract][Full Text] [Related]
19. Cellular and subcellular localization of Rab10 and phospho-T73 Rab10 in the mouse and human brain. Singh V; Menard MA; Serrano GE; Beach TG; Zhao HT; Riley-DiPaolo A; Subrahmanian N; LaVoie MJ; Volpicelli-Daley LA Acta Neuropathol Commun; 2023 Dec; 11(1):201. PubMed ID: 38110990 [TBL] [Abstract][Full Text] [Related]
20. LRRK2 impairs autophagy by mediating phosphorylation of leucyl-tRNA synthetase. Ho DH; Kim H; Nam D; Sim H; Kim J; Kim HG; Son I; Seol W Cell Biochem Funct; 2018 Dec; 36(8):431-442. PubMed ID: 30411383 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]